发明名称 ERYTHROPOIETIN IN SUBPOLYCYTHEMIC DOSES FOR TREATING DIABETES
摘要 <p>Use of erythropoetin (EPO) and/or its derivatives for stimulating, in endothelial precursor cells (EPC), any of physiological mobilization; proliferation; differentiation to endothelial cells and/or migration, in the direction of an angiogenic or vasculogenic stimulus. Independent claims are also included for the following: (1) use of EPO and/or its derivatives for stimulating formation of endothelial cells (EC) and/or for vasculogenesis; (2) use of EPO to produce a transplantable EC product; (3) use of EPO for treating a tissue or organ transplant; (4) use of EPO for pretreatment of tissue or organ transplants; (5) use of EPO to prepare implantable or transplantable, cell-containing in vitro organ or tissue systems; (6) use of EPO for coating vascular prostheses or heart valves; and (7) pharmaceutical composition containing (a) EPO, its derivatives, analogs, modifications or muteins and (b) at least one of vascular endothelial growth factor, PIGF (not defined), granulocyte-macrophage colony-stimulating factor and/or a hydroxymethyl glutarate-CoA reductase inhibitor. - ACTIVITY : Antilipemic; Antidiabetic; Antiinflammatory; Antiarteriosclerosis; Cardiant; Vasotropic; Antianginal; Gynecological; Hypotensive; Nephrotropic. No details of tests for any of these activities are given. - MECHANISM OF ACTION : Treatment with EPO increases adhesion of EPC and stimulates formation of endothelial tissue and blood vessels.</p>
申请公布号 EP1779862(B1) 申请公布日期 2010.05.19
申请号 EP20070001689 申请日期 2003.07.25
申请人 EPOPLUS GMBH & CO. KG 发明人 BAHLMANN, FERDINAND HERMANN, DR.;HALLER, HERMANN, PROF. DR.
分类号 A61K38/18;A61K38/19;A61P3/10;A61P9/00 主分类号 A61K38/18
代理机构 代理人
主权项
地址